Anavex Life Sciences, a New York-based biopharmaceutical company, develops therapeutics for neurodegenerative diseases and employs 40 staff. Its lead compound, ANAVEX 2-73, targets Alzheimer's and Parkinson's diseases.
AVXL has been in the news recently: 180 Life Sciences Corp. saw a significant increase in its share price after announcing it holds over $349 million in Ethereum as part of its updated treasury strategy. The broader U.S. stock market also experienced gains, with the Dow Jones index rising by approximately 500 points on Tuesday and an additional 250 points on Wednesday.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
